|... after diagnosis:||"How dangerous is my melanoma?"|
|... in the early stage (I):||"Is the follow-up care sufficient?"|
|... in the intermediate stage (II):||"Is cancer treatment after surgery necessary?"|
|... in the advanced stage (III):||“Are intensified cancer treatments required?”
... "Am I protected against a relapse?"
|Thin melanoma||These melanoma patients have an excellent prognosis. Yet this group harbors with 25% the largest proportion of melanoma mortality. MelaGenix identifies high-risk patients in this group.|
|Intermediate stage II||MelaGenix validates or corrects SLN analysis of melanoma patients and enables evidence-based treatment decisions.|
|Advanced stage III||These melanoma patients can enroll in adjuvant clinical trials. By identification of high-risk patients, MelaGenix increases efficiency of these studies (companion diagnostic).|